Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 14/20 | 0.53 |
| ▸ | PPARG | P37231 | 13/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550691 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL2221549 | 0.83 | PPARG (0.39) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL30559867 | 0.81 | PPARG (0.77) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL8935913 | 0.81 | PPARG (0.77) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL8935921 | 0.81 | PPARG (0.77) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL2222030 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL2222296 | 0.80 | SCN9A (0.40) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL2222294 | 0.80 | PPARG (0.39) | PPARAPPARGAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2221558 | 0.79 | PPARG (0.36) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL2223258 | 0.79 | PPARG (0.36) | SMN1; SMN2PPARAPPARGAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-11-08 | — | — | US | disclosed |
| EP-2516385-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012087372-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011087837-A9 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011087837-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | CBR3, CBR1, Q6ZSR9 | SMN1; SMN2 2728/4885PPARA 3944/4885PPARG 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.